RESUMO
Cutaneous pain is a common symptom of skin disease, and available therapies are inadequate. We developed a neural selective and injectable method of cryoneurolysis with ice slurry, which leads to a long-lasting decrease in mechanical pain. The aim of this study is to determine whether slurry injection reduces cutaneous pain without inducing the side effects associated with conventional cryoneurolysis. Using the rat sciatic nerve, we examined the effects of slurry on nerve structure and function in comparison with the effects of a Food and Drug Administrationâapproved cryoneurolysis device (Iovera). Coherent anti-Stokes Raman scattering microscopy and immunofluorescence staining were used to investigate histological effects on the sciatic nerve and on downstream cutaneous nerve fibers. Complete Freund's Adjuvant model of cutaneous pain was used to study the effect of the slurry on reducing pain. Structural changes in myelin induced by slurry were comparable with those induced by Iovera, which uses much colder temperatures. Compared with that of Iovera, the decrease in mechanical pain due to slurry was less profound but lasted longer without signs of dysesthesia. Slurry did not cause a reduction of epidermal nerve fibers or a change in thermal pain sensitivity. Slurry-treated rats showed reduced cutaneous mechanical pain in response to Complete Freund's Adjuvant. Slurry injection can be used to successfully reduce cutaneous pain without causing dysesthesia.
Assuntos
Gelo , Dermatopatias , Ratos , Animais , Adjuvante de Freund/farmacologia , Ratos Sprague-Dawley , Parestesia , Dor/etiologiaRESUMO
BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disease with persistent and severe itch among its hallmark features. Significant increases in type 2 cytokines (ie, IL-4, IL-13, IL-31) have been documented in acute atopic dermatitis lesions and lead to multifaceted downstream effects, including inflammation, epidermal barrier dysfunction, and itch. OBJECTIVE: The primary objective of preclinical studies reported here was to test direct effects of IL-13 and an anti-IL-13 mAb, lebrikizumab, in a human dorsal root ganglion model in itch amplification, neuronal excitability, and transcriptional downstream targets. METHODS: Neuroactive effects were assessed via live cell calcium imaging, electric field stimulation, and RNA sequencing of human dorsal root ganglia stimulated with IL-13 alone or in combination with lebrikizumab. RESULTS: These preclinical findings suggest that IL-13 plays a direct enhancer role in multiple itch and neuroactive pathways as well as transcriptional downstream effects, and provide key insights into the mechanistic basis for lebrikizumab's anti-itch effects. CONCLUSION: IL-13 is a potent enhancer of neuronal responses to different itch stimuli, consistent with the neuroimmune axis contributing to chronic itch-associated inflammatory skin disease, and blockade of this cytokine pathway may provide a therapeutic approach.
Assuntos
Dermatite Atópica , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Antipruriginosos/farmacologia , Citocinas/metabolismo , Humanos , Prurido , PeleRESUMO
Numerous inflammatory skin disorders display a high prevalence of itch. The Mas-related G protein coupled receptor X2 (MRGPRX2) has been shown to modulate itch by inducing non-IgE-mediated mast cell degranulation and the release of endogenous inducers of pruritus. Various substances collectively known as basic secretagogues, which include inflammatory peptides and certain drugs, can trigger MRGPRX2 and thereby induce pseudo-allergic reactions characterized by histamine and protease release as well as inflammation. Here, we investigated the capacity of an immunomodulatory single-stranded oligonucleotide (ssON) to modulate IgE-independent mast cell degranulation and, more specifically, its ability to inhibit the basic secretagogues compound 48/80 (C48/80)-and LL-37 in vitro and in vivo. We examined the effect of ssON on MRGPRX2 activation in vitro by measuring degranulation in a human mast cell line (LAD2) and calcium influx in MRGPRX2-transfected HEK293 cells. To determine the effect of ssON on itch, we performed behavioral studies in established mouse models and collected skin biopsies for histological analysis. Additionally, with the use of a rosacea mouse model and RT-qPCR, we investigated the effect on ssON on LL-37-induced inflammation. We reveal that both mast cell degranulation and calcium influx in MRGPRX2 transfected HEK293 cells, induced by the antimicrobial peptide LL-37 and the basic secretagogue C48/80, are effectively inhibited by ssON in a dose-dependent manner. Further, ssON demonstrates a capability to inhibit LL-37 and C48/80 activation in vivo in two mouse models. We show that intradermal injection of ssON in mice is able to block itch induced via C48/80 in a dose-dependent manner. Histological staining revealed that ssON inhibits acute mast cell degranulation in murine skin treated with C48/80. Lastly, we show that ssON treatment ameliorates LL-37-induced inflammation in a rosacea mouse model. Since there is a need for new therapeutics targeting non-IgE-mediated activation of mast cells, ssON could be used as a prospective drug candidate to resolve itch and inflammation in certain dermatoses.
Assuntos
DNA de Cadeia Simples/genética , Inflamação/genética , Mastócitos/imunologia , Proteínas do Tecido Nervoso/metabolismo , Oligonucleotídeos/genética , Prurido/genética , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Neuropeptídeos/metabolismo , Animais , Peptídeos Catiônicos Antimicrobianos/imunologia , Comportamento Animal , Degranulação Celular , Modelos Animais de Doenças , Células HEK293 , Humanos , Inflamação/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Prurido/imunologia , p-Metoxi-N-metilfenetilamina/imunologia , CatelicidinasRESUMO
Itch is a topic to which everyone can relate. The physiological roles of itch are increasingly understood and appreciated. The pathophysiological consequences of itch impact quality of life as much as pain. These dynamics have led to increasingly deep dives into the mechanisms that underlie and contribute to the sensation of itch. When the prior review on the physiology of itching was published in this journal in 1941, itch was a black box of interest to a small number of neuroscientists and dermatologists. Itch is now appreciated as a complex and colorful Rubik's cube. Acute and chronic itch are being carefully scratched apart and reassembled by puzzle solvers across the biomedical spectrum. New mediators are being identified. Mechanisms blur boundaries of the circuitry that blend neuroscience and immunology. Measures involve psychophysics and behavioral psychology. The efforts associated with these approaches are positively impacting the care of itchy patients. There is now the potential to markedly alleviate chronic itch, a condition that does not end life, but often ruins it. We review the itch field and provide a current understanding of the pathophysiology of itch. Itch is a disease, not only a symptom of disease.
Assuntos
Prurido/metabolismo , Prurido/fisiopatologia , Animais , Humanos , Neurônios/fisiologia , Pele/inervação , Medula Espinal/citologia , Medula Espinal/fisiologiaRESUMO
Why do we have the sensation of itch and the associated scratching response? The conventional explanation is that arthropods and other environmental irritants elicit the sensation of itch that then leads to scratching and removal of the stimulus. This explanation is reasonable yet is too limiting for this fascinating sensory phenomenon and the associated somatic (voluntary) response of scratching. We delve into other explanations here. Some of these explanations fit within current areas of basic and clinical knowledge while others are speculative and may help to frame future discussions and study.
Assuntos
Prurido/etiologia , Animais , Evolução Biológica , HumanosRESUMO
Itch, inflammation, and atopic dermatitis are associated with activation of PAR2. Affecting PAR2 activity presents a number of challenges. Here, a cell-penetrating peptide, termed a pepducin, circumvents these challenges by preventing the receptor from coupling to G proteins. The pepducin modulates several models of itch, inflammation, and atopic dermatitis.
Assuntos
Dermatite Atópica , Eczema , Humanos , Inflamação , PruridoRESUMO
Atopic dermatitis is a common cutaneous disorder characterized by severe itch, chronic inflammation, and increased nerve fiber density. It has been assumed that the neural changes are in response to ongoing inflammation. We used in vivo imaging over time of fluorescently labeled peripheral sensory nerves during epicutaneous sensitization to ovalbumin in an allergic mouse model of atopic dermatitis. Visualization of cutaneous nerve branches and blood vessels sequentially over months revealed that peripheral sensory nerves begin to pathfind within 48 hours of antigen exposure. Innervation density and arbor complexity of neuropeptidergic fibers in the skin increased within days. Neural sprouting preceded changes in vascularization, vascular permeability, and immune infiltration. Blocking neural activation during periods of sensitization prevented ovalbumin-induced changes in neural recruitment and pattern reorganization, as well as subsequent inflammatory infiltrates and scratching behavior. These data implicate different roles for recently identified itch molecules in modulating various steps in the inflammatory response. Thus, in contrast to the traditional view that neural changes are reactive to inflammation and scratching, these data suggest that allergic stimulation in a chronic eczema model requires neural recruitment and activation early in the process for the elaboration and maintenance of the inflammatory cascade.
RESUMO
Chronic itch is a clinically challenging yet scientifically remarkable and complex process. Increasing understanding of the pathophysiology of chronic itch is leading to targeted therapeutic approaches that are now dramatically improving quality of life. This improvement will accelerate as the tools of basic and clinical research continue to be applied to this previously intractable problem.
Assuntos
Prurido/etiologia , Prurido/fisiopatologia , Comunicação Celular , Sensibilização do Sistema Nervoso Central , Doença Crônica , Humanos , Prurido/tratamento farmacológico , Células Receptoras SensoriaisRESUMO
To protect our body systems, there is a constant interactive conversation between the skin nervous and immune system. Important elements of this conversation in the skin include mast cells, basophils, and sensory nerve fibers. These cells employ a vast array of sensors that detect danger and react accordingly. This reaction, summarized as neurogenic inflammation, manifests at the conscious level as sensations including pain and itch. Here we provide a perspective on the blossoming knowledge that is illuminating connections between mast cells, basophils, and sensory nerve fibers in the mediation of itch. We discuss established mediators and receptors, in particular cytokine and neuropeptide pathways, upstream proteases, and proteinase-activated receptors, and the emerging role of mas-related G-protein-coupled receptors in itch.
Assuntos
Basófilos/imunologia , Mastócitos/imunologia , Prurido/imunologia , Pele/imunologia , Animais , Citocinas/metabolismo , Humanos , Receptores Acoplados a Proteínas G/metabolismo , Pele/patologiaAssuntos
Cisteína Proteases/imunologia , Mucuna/imunologia , Proteínas do Tecido Nervoso/imunologia , Proteínas de Plantas/imunologia , Prurido/imunologia , Receptores Acoplados a Proteínas G/imunologia , Receptores de Neuropeptídeos/imunologia , Degranulação Celular/imunologia , Cisteína Proteases/metabolismo , Células HEK293 , Histamina/imunologia , Histamina/metabolismo , Humanos , Mastócitos/imunologia , Mucuna/química , Proteínas do Tecido Nervoso/metabolismo , Proteínas de Plantas/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Neuropeptídeos/metabolismo , Transdução de Sinais/imunologia , Pele/citologia , Pele/imunologiaRESUMO
Cysteine and serine proteases function via protease-activated and mas-related G-protein-coupled receptors (Mrgprs) to contribute to allergy and inflammation. Der p1 is a cysteine protease and major allergen from the house dust mite and is associated with allergic rhinitis and allergic asthma. Der p1 activates protease-activated receptor 2 and induces the release of the pro-inflammatory cytokine IL-6 from cells. However, the possibility that Der p1 acts on Mrgprs has not been considered. We report here that ratiometric calcium imaging reveals that Der p1 activates the human receptor MRGPRX1 and the mouse homolog MrgprC11, implicated previously in itch. Der p1 cleavage of N-terminal receptor peptides followed by site-directed mutagenesis of the cleavage sites links receptor activation to specific amino acid residues. Der p1 also induced the release of IL-6 from heterologous cells expressing MRGPRX1. In summary, activation of Mrgprs by the allergen Der p1 may contribute to inflammation.
Assuntos
Antígenos de Dermatophagoides/metabolismo , Proteínas de Artrópodes/metabolismo , Cisteína Endopeptidases/metabolismo , Cisteína Proteases/metabolismo , Hipersensibilidade/metabolismo , Proteólise , Pyroglyphidae/enzimologia , Receptores Acoplados a Proteínas G/metabolismo , Células A549 , Animais , Antígenos de Dermatophagoides/farmacologia , Proteínas de Artrópodes/farmacologia , Cisteína Endopeptidases/farmacologia , Cisteína Proteases/farmacologia , Células HeLa , Humanos , Hipersensibilidade/genética , Inflamação , Interleucina-6/genética , Interleucina-6/metabolismo , Camundongos , Domínios Proteicos , Receptores Acoplados a Proteínas G/genéticaAssuntos
Arginina/metabolismo , Ácido Glutâmico/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Neuropeptídeos/metabolismo , Substância P/metabolismo , p-Metoxi-N-metilfenetilamina/metabolismo , Células HEK293 , Células HeLa , Humanos , Modelos Moleculares , Proteínas do Tecido Nervoso/genética , Prurido , Receptores Acoplados a Proteínas G/genética , Receptores de Neuropeptídeos/genéticaRESUMO
Vancoymycin causes red man syndrome, an itchy erythematous eruption involving the face, neck and upper torso. Atopic dermatitis also manifests itch and erythema, and staphylococcus δ-toxin contributes to this process. The antibiotic and toxin each provoke mast cell degranulation but the mechanism had not been understood. We have determined that these compounds evoke degranulation via interaction with the same receptor, MRGPRX2, on mast cells. A receptor antagonist inhibits this process. Antagonists of this receptor may have therapeutic potential.
RESUMO
BACKGROUND: Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE: We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients. METHODS: cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of São Paulo state, using enzyme-linked immunosorbent assay. FINDINGS: Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN CONCLUSION: High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.
Assuntos
Anticorpos/sangue , Proteínas de Insetos/análise , Insetos Vetores/química , Leishmaniose Cutânea/sangue , Psychodidae/química , Animais , Anticorpos/imunologia , Brasil , Estudos de Casos e Controles , Doenças Endêmicas , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Immunoblotting , Proteínas de Insetos/imunologia , Insetos Vetores/classificação , Leishmaniose Cutânea/imunologia , Masculino , Reação em Cadeia da Polimerase , Psychodidae/classificação , Coelhos , Análise de Sequência de DNARESUMO
Sun and colleagues (2017) find that individual Grp+ spinal interneurons can respond to and distinguish between stimuli that provoke itch or pain. The nociceptive response is limited by enkaphalin-expressing interneurons that are connected synaptically to the Grp+ neurons.
Assuntos
Gânglios Espinais/citologia , Peptídeo Liberador de Gastrina/metabolismo , Interneurônios/metabolismo , Neurônios/metabolismo , Dor/fisiopatologia , Medula Espinal/fisiopatologia , Animais , HumanosRESUMO
BACKGROUND: Substance P (SP) is linked to itch and inflammation through activation of receptors on mast cells and sensory neurons. There is increasing evidence that SP functions through Mas-related G protein-coupled receptors (Mrgprs) in addition to its conventional receptor, neurokinin-1. OBJECTIVE: Because Mrgprs mediate some aspects of inflammation that had been considered mediated by neurokinin-1 receptor (NK-1R), we sought to determine whether itch induced by SP can also be mediated by Mrgprs. METHODS: Genetic and pharmacologic approaches were used to evaluate the contribution of Mrgprs to SP-induced scratching behavior and activation of cultured dorsal root ganglion neurons from mice. RESULTS: SP-induced scratching behavior and activation of cultured dorsal root ganglion neurons was dependent on Mrgprs rather than NK-1R. CONCLUSION: We deduce that SP activates MrgprA1 on sensory neurons rather than NK-1R to induce itch.
Assuntos
Gânglios Espinais/citologia , Prurido/genética , Receptores Acoplados a Proteínas G/genética , Adolescente , Adulto , Idoso , Animais , Capsaicina/farmacologia , Células Cultivadas , Feminino , Humanos , Masculino , Camundongos Transgênicos , Pessoa de Meia-Idade , Prurido/induzido quimicamente , Receptores da Neurocinina-1/genética , Células Receptoras Sensoriais/efeitos dos fármacos , Substância P , Adulto JovemRESUMO
BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients. METHODS cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of São Paulo state, using enzyme-linked immunosorbent assay. FINDINGS Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN CONCLUSION High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.
Assuntos
Animais , Masculino , Feminino , Coelhos , Leishmaniose Cutânea/imunologia , Leishmaniose Cutânea/sangue , Proteínas de Insetos/imunologia , Insetos Vetores/classificação , Anticorpos/imunologia , Anticorpos/sangue , Psychodidae/química , Brasil , Ensaio de Imunoadsorção Enzimática , Immunoblotting , Estudos de Casos e Controles , Reação em Cadeia da Polimerase , Proteínas de Insetos/análise , Doenças EndêmicasRESUMO
Intradermal administration of chloroquine (CQ) provokes scratching behavior in mice. Chloroquine-induced itch is histamine-independent and we have reported that the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway is involved in CQ-induced scratching behavior in mice. Previous studies have demonstrated that activation of N-methyl-d-aspartate receptors (NMDARs) induces NO production. Here we show that NMDAR antagonists significantly decrease CQ-induced scratching in mice while a non-effective dose of an NMDAR agonist potentiates the scratching behavior provoked by sub-effective doses of CQ. In contrast, combined pre-treatment with sub-effective doses of an NMDAR antagonist, MK-801, and the NO synthase inhibitor, L-N-nitro arginine methyl ester (L-NAME), decreases CQ-induced scrat-ching behavior. While intradermal administration of CQ significantly increases the concentration of intradermal nitrite, the end product of NO metabolism, effective doses of intraperitoneal and intradermal MK-801 significantly decrease intradermal nitrite levels. Likewise, administration of an effective dose of L-NAME significantly decreases CQ-induced nitrite production. We conclude that the NMDA/NO pathway in the skin modulates CQ-induced scratching behavior.